title: Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo.
abstract: Neuromedin B (NMB), a member of the mammalian bombesin-like peptide family, and its receptor were aberrantly expressed in vascularized solid tumors. Here, the NMB receptor (NMB-R) antagonist PD168368 specifically inhibited both NMB-induced in vivo and in vitro angiogenesis. In addition, PD168368 showed growth inhibitory effects on MDA-MB-231 breast cancer cells by inducing cell cycle arrest and apoptosis. Furthermore, PD168368 effectively suppressed tumor growth in a xenograft model of breast tumor in vivo. Overall, NMB-R antagonist exhibited a significant antitumor activity by simultaneously inhibiting neovascularization and cancer cell growth, thereby suggesting that NMB-R could be a potential therapeutic target for cancer treatment.
authors: School of Dentistry, Pusan National University, Yangsan 626-870, South Korea.
authors: Hyun-Joo
authors: HJ
authors: Park
authors: Su-Ryun
authors: SR
authors: Kim
authors: Mi-Kyoung
authors: MK
authors: Kim
authors: Kyu-Sil
authors: KS
authors: Choi
authors: Hye-Ock
authors: HO
authors: Jang
authors: Il
authors: I
authors: Yun
authors: Soo-Kyung
authors: SK
authors: Bae
authors: Moon-Kyoung
authors: MK
authors: Bae
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D048708:Cell Growth Processes / Q000187:drug effects; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D007211:Indoles; C419604:PD 168368; D011725:Pyridines; D018004:Receptors, Bombesin